Barbara Gutierrez: Not commenting on the specific numbers, I think a couple of things. It’s an improvement over Q1. And so, we’re positive about the trajectory that we’re on Q2 over Q1. And as we continue to grow, again, we think that it will be marginally dropped disproportionately to the CLCM and the EBITDA margin. So, I guess I would say, future quarters should drive us proportionately.
Patrick Blair: Yes, I would just summarize it. The growth is, sort of everything right now. Growth is really going to help bring a lot of our ratios, sort of in the balance. And we do expect a positive trend from this past quarter going forward. I think the exact, sort of rate and slope is going to depend on a number of things. It’s going to depend on how many new participants we enroll. It’s going to depend on the speed at which we can grow into that capacity. And that’s dependent on, sort of what’s called the post audit, sort of baseline that we have to find, but as we add new participants, we think that the overall frailty of the population should come down on balance and that helps with our leverage. We need to drive center attendance up.
As we drive center attendance up, we can get more eyes on the patients and hopefully have an impact to the cause. And then we put a lot of operational efficiency initiatives in place that should yield some dividends as well. So, I think there’s part of the reason we just need a little time is to really understand how all these factors are going to work together. And I think overall if we can grow the business as we anticipate, we should see a positive trend in earnings moving forward.
Lisa Gill: Okay, great. And Patrick, I appreciate that you’re not prepared to give guidance. How should I think about this though? Will it be that once all the sanctions are gone, maybe next quarter we’ll think about guidance or is this something that we should think you’ll give us guidance for 2024, I’m just curious how you’re thinking about it internally?
Patrick Blair: Well, we’re still having that discussion internally. As we said, we really want to have a bit more time to see the baseline on our costs and how quickly our growth ramps up, but I would say that, generally speaking, guidance in fiscal year 2024 is more likely. And we certainly want to provide the guidance as soon as we can, but at the same time it’s going to take a bit of time just to understand all the held pieces and parts fit together. I feel like we’re going to get more confidence on revenue probably sooner than maybe some of the EBITDA side. And so, we’ll look at this in pieces.
Lisa Gill: Great. Thanks for the comments.
Operator: Thank you. Our next question comes from the line of Jamie Perse with Goldman Sachs. Your line is open.
Jamie Perse: Hey, good afternoon. Congrats on getting to lot of these audits. I know that was a big lift. First, just on the risk pool and adding some new patients that are lower risk than your average today. Can you help us think about what the margin impact of that looks like? Are lower risk patients actually better margin or just any color you can give on how to think about the risk pool moving down impact on financials?